Mycobacterium (e.g., Mycobacterium Tuberculosis, Calmette-guerin Bacillus (i.e., Bcg), Etc.) Patents (Class 424/248.1)
  • Patent number: 10610577
    Abstract: An immunomodulator is for use in the treatment, reduction, inhibition or control of a neoplastic disease in a patient intended to undergo checkpoint inhibition therapy, simultaneously, separately or sequentially with administration of the immunomodulator. The immunomodulator preferably includes a whole cell Mycobacterium, such as M. vaccae or M. obuense.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: April 7, 2020
    Assignee: IMMODULON THERAPEUTICS LIMITED
    Inventors: Charles Akle, John Grange, Kevin Bilyard
  • Patent number: 10578617
    Abstract: There is provided a diagnostic reagent for use in the detection of M. bovis or M. tuberculosis infection in an animal, comprising a peptide which has an epitope from Mycobacterium bovis hypothetic protein Mb3645c (SEQ ID NO: 1) or an epitope from a polypeptide having at least 76% identity with SEQ ID NO: 1.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: March 3, 2020
    Assignee: The Secretary of State for Environment, Food and Rural Affairs
    Inventors: Hans Martin Vordermeier, Benjamin Sidders, Neil Graham Stoker, Katie Ewer
  • Patent number: 10525118
    Abstract: The invention relates to a recombinant Mycobacterium cell for use as an immunotherapeutic agent in the treatment of cancer, particularly in the treatment of solid tumors. More particularly, the invention relates to the immunotherapy of bladder carcinoma.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: January 7, 2020
    Assignee: Vakzine Projekt Management GmbH
    Inventor: Leander Grode
  • Patent number: 10512680
    Abstract: The present invention relates to a method for the preparation of an immunogenic composition for the treatment and/or prophylaxis of mycoplasma infections in a subject comprising the cultivation of mycoplasma bacteria in a serum-reduced or swine serum-free, eukaryotic cell system; obtaining an antigen of the mycoplasma bacteria; and addition of a pharmaceutically acceptable carrier. Further, the present invention relates to the immunogenic composition obtainable by said method and a method for immunizing a subject comprising the administration of said immunogenic composition to a subject.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: December 24, 2019
    Inventors: Dianna M. Murphy Jordan, Brian Thomas Martinson, Christine Margaret Muehlenthaler, Axel Neubauer, Arun V. Iyer
  • Patent number: 10478482
    Abstract: The present invention provides new immunological compositions and vaccines comprising selected M. tuberculosis antigens and antigenic peptides as well as nucleic acids encoding said antigens for use in the prevention, prophylaxis and treatment of mycobacterial infection, especially tuberculosis. In particular the invention provides recombinant BCG based vaccines in which one or more of the selected M. tuberculosis antigens are over expressed. The invention further provides isolated peptides for use in methods for diagnosing, characterizing, or classifying mycobacterial infections.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: November 19, 2019
    Assignee: ALARUM DEVELOPMENT LTD
    Inventor: Markus Maeurer
  • Patent number: 10441652
    Abstract: A method is provided for increasing an immunological response to a target antigen in an animal by administering an immunogenic amount of a vaccine comprising a polypeptide conjugate comprising the target antigen conjugated to a carrier polypeptide by means of a linker polypeptide which is rich in predicted linear B-cell epitopes.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: October 15, 2019
    Assignee: Braasch Biotech LLC
    Inventor: Keith N. Haffer
  • Patent number: 10428122
    Abstract: The present disclosure provides fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: October 1, 2019
    Assignee: International AIDS Vaccine Initiative, Inc.
    Inventors: Ravi P. Anantha, Thomas G. Evans, Aurelio M. Bonavia
  • Patent number: 10143702
    Abstract: Oral administration of a solid dosage form of the present invention comprising an effective amount of rifabutin, an effective amount of clarithromycin, an effective amount of clofazimine, and an effective amount of an absorption enhancer, is used to treat a subject suffering from, or susceptible to, Mycobacterium avium subspecies paratuberculosis infection. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in the increased metabolism of clarithromycin caused by rifabutin. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in the metabolism of rifabutin caused by clarithromycin. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in risk of a subject developing leucopenia or uveitis as a result of rifabutin.
    Type: Grant
    Filed: January 2, 2018
    Date of Patent: December 4, 2018
    Assignee: RedHill Biopharma Ltd.
    Inventors: Thomas Julius Borody, Patrick Gosselin
  • Patent number: 10105379
    Abstract: Oral administration of a solid dosage form of the present invention comprising an effective amount of rifabutin, an effective amount of clarithromycin, an effective amount of clofazimine, and an effective amount of an absorption enhancer, is used to treat a subject suffering from, or susceptible to, Mycobacterium avium subspecies paratuberculosis infection. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in the increased metabolism of clarithromycin caused by rifabutin. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in the metabolism of rifabutin caused by clarithromycin. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in risk of a subject developing leucopenia or uveitis as a result of rifabutin.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: October 23, 2018
    Assignee: Red-Hill Biopharma Ltd.
    Inventors: Thomas Julius Borody, Patrick Gosselin
  • Patent number: 10092592
    Abstract: The present invention belongs to the field of medicine technology, particularly relating to an application of cyclic dinucleotide (cGAMP) in tumor treatment. Researches carried out in the present invention show that, cGAMP can inhibit growth of many types of tumor cells, with remarkable anti-tumor effect, thus, it can be used in preparation of anti-tumor drugs; and the prepared anti-tumor drugs have low toxicity and favorable effect. Proved by a subcutaneous tumor model in nude mice, cGAMP has a remarkable inhibition effect on tumors of human gastric carcinoma cell line MNK-45, human lung adenocarcinoma cell line A549, human colorectal carcinoma cell line Lovo, human hepatocellular carcinoma cell line SMMC-7721, human prostatic carcinoma cell line PC-3 and human pancreatic carcinoma cell SW1990, which are subcutaneously implanted in nude mice, and also proved by animal acute toxicity experiment. cGAMP has a relatively low acute toxicity, therefore and may be used for preparing anti-tumor drugs.
    Type: Grant
    Filed: April 20, 2015
    Date of Patent: October 9, 2018
    Assignee: Fudan University
    Inventors: Xiangshi Tan, Tiejun Li, Qiming Xu, Jie Pan, Yaocheng Rui, Hao Cheng, Yuefan Zhang
  • Patent number: 10071124
    Abstract: The present invention relates to treatment or prevention of post-traumatic stress disorder (PTSD). In particular, the present invention relates to an isolated Mycobacterium, for use in the prevention of PTSD and the symptoms associated with such a disorder. Also provided are methods of improving resilience in a subject by administering a therapeutically effective amount of isolated Mycobacterium.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: September 11, 2018
    Assignee: IMMODULON THERAPEUTICS LIMITED
    Inventors: Charles Akle, John Grange
  • Patent number: 10072259
    Abstract: Compositions and techniques for the extraction, enrichment and isolation of nucleic acids from yeast in a whole blood sample using amine monomers are disclosed herein.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: September 11, 2018
    Assignee: Abbott Molecular Inc.
    Inventor: Gerard J. Gundling
  • Patent number: 10053687
    Abstract: Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen M. tuberculosis and their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: August 21, 2018
    Assignee: Immport Therapeutics, Inc.
    Inventors: Philip Felgner, Xiaowu Liang, Maria Laura Gennaro
  • Patent number: 9974847
    Abstract: The invention is within the field of immunology and microbiology, more specifically the field of mycobacteriology and is related to immunotherapy and prophylaxis of tuberculosis and related diseases. The composition useful for these purposes is disclosed, including the methods of using said composition.
    Type: Grant
    Filed: October 4, 2010
    Date of Patent: May 22, 2018
    Assignee: IMMUNITOR USA, INC.
    Inventors: Aldar Bourinbaiar, Vichai Jarathitikal
  • Patent number: 9714275
    Abstract: Cancer cells when treated with cisplatin, paclitaxel, gemcitabine, Mycobacterium w or combination there of shows altered protein profile. Thus altered protein profile has at least one protein commonly expressed or over expressed. The commonly expressed or over expressed protein induces immune response specific to cancer cells (homologue and hetrologus) of tissue/organ of origin. The immune response generated by administration of commonly expressed or over expressed antigen not reactive to normal cells and cancer cells or different tissue/organ of origin.
    Type: Grant
    Filed: July 4, 2012
    Date of Patent: July 25, 2017
    Assignee: Cadila Pharmaceuticals Ltd.
    Inventors: Indravadan Ambalal Modi, Rajiv Indravadan Modi, Bakulesh Mafatlal Khamar, Chandreshwar Prasad Shukla, Vipul Sitaram Thakkar, Nirav Manojkumar Desai
  • Patent number: 9663758
    Abstract: Described herein is a mycobacterium mutant, comprising at least one mutation in at least one gene sequence encoding global gene regulators (GGRs) selected from the group consisting of sigH, sigL, sigE, ECF-1, and mixtures thereof, wherein the GGR gene is at least partially inactivated. Described herein also is a vaccine based on the mutant and a method of differentiating between subjects that have been infected with mycobacterium and subjects that have not been infected with mycobacterium or have been vaccinated with a mycobacterium vaccine.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: May 30, 2017
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: Adel M. Talaat
  • Patent number: 9513281
    Abstract: The invention provides methods, compositions, devices, and kits relating to the use of cholesterol-dependent cytolysins (e.g., PFOs) for measuring intracellular mitochondrial activity.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: December 6, 2016
    Assignees: BAYSTATE MEDICAL CENTER, INC., UNIVERSITY OF MASSACHUSETTS
    Inventors: Nagendra Yadava, Alejandro Pablo Heuck, Chul Kim
  • Patent number: 9415078
    Abstract: The present invention relates to increase in survival of mammals suffering from desmocollin 3 expressing cancers. Mycobacterium w is administered to mammals suffering from desmocollin-3 expressing cancers. The administration of Mycobacterium w results in control of tumor and improvement in survival. Mycobacterium w can also be used along with other therapeutic agent(s)/modalities as per the requirement. The squamous type of non small cell lung cancer is known to be desmocollin-3 expressing cancer. Other cancers also express desmocollin-3.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: August 16, 2016
    Assignee: Cadila Pharmaceuticals Ltd.
    Inventors: Bakulesh Mafatlal Khamar, Indravadan Ambalal Modi
  • Patent number: 9404923
    Abstract: The present invention relates to novel peptides that may be used in whole or in combination for the detection of Mycobacterium tuberculosis infection. In particular, the present invention relates to compositions and methods involving detection of antibodies contained in the blood of non-human primates that arise from an infection from M. tuberculosis or vaccination using an epitope specific inoculation. More particularly, the present invention provides a means to distinguish early, active, and latent M. tuberculosis infection. More particularly, the present invention describes an immunological diagnostic mechanism for the detection of M. tuberculosis infection.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: August 2, 2016
    Assignee: INTUITIVE BIOSCIENCES, INC.
    Inventor: Kimberly Luke
  • Patent number: 9328350
    Abstract: The invention relates to a recombinant Mycobacterium cell for use as a vaccine.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: May 3, 2016
    Assignees: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V., Vakzine Projekt Management GmbH
    Inventors: Christiane Desel, Stefan H. E. Kaufmann, Silke Bandermann, Leander Grode
  • Patent number: 9314477
    Abstract: Oral administration of a solid dosage form of the present invention comprising an effective amount of rifabutin, an effective amount of clarithromycin, an effective amount of clofazimine, and an effective amount of an absorption enhancer, is used to treat a subject suffering from, or susceptible to, Mycobacterium avium subspecies paratuberculosis infection. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in the increased metabolism of clarithromycin caused by rifabutin. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in the metabolism of rifabutin caused by clarithromycin. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in risk of a subject developing leucopenia or uveitis as a result of rifabutin.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: April 19, 2016
    Assignee: RedHill Biopharma Ltd.
    Inventors: Thomas Julius Borody, Patrick Gosselin
  • Patent number: 9198926
    Abstract: A composition of the present invention comprises an effective amount of rifabutin, an effective amount of clarithromycin, an effective amount of clofazimine, and an effective amount of an absorption enhancer, wherein the effective amount of the absorption enhancer is sufficient so that, when the composition is administered to a patient, an overall metabolism of clarithromycin as caused by rifabutin is reduced by shifting competing metabolism of rifabutin and clarithromycin so as to result in more active clarithromycin.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: December 1, 2015
    Assignee: RedHill Biopharma Ltd.
    Inventors: Thomas Julius Borody, Patrick Gosselin
  • Patent number: 9078875
    Abstract: An adjuvant combination that stimulates immune activation or response includes a hydrophobic immune adjuvant and a pathogen derived lipoprotein that chaperones the hydrophobic immune adjuvant to an immune receptor.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: July 14, 2015
    Assignee: Case Western Reserve University
    Inventors: Clifford Harding, W. Henry Boom, Michael G. Drage, Nicole D. Pecora
  • Patent number: 9072763
    Abstract: The present disclosure provides improved compositions comprising rifabutin, clarithromycin, and clofazimine for use in the treatment of Inflammatory Bowel Diseases. In one instance, the compositions may comprise a formulation of rifabutin, clarithromycin, and clofazimine in a single dosage form, such as a capsule, tablet, etc., with one or more specific excipients.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: July 7, 2015
    Assignee: RedHill Biopharma Ltd.
    Inventors: Thomas Julius Borody, Patrick Gosselin
  • Publication number: 20150140039
    Abstract: The present invention concerns embodiments for determining whether an individual in need of immunotherapy will be responsive to the immunotherapy. Determination of one or more SNPs in particular genes is predictive of responsiveness to immunotherapy, particularly in individuals that have melanoma, for example. In certain embodiments, the SNPs are in ITGB2, SP1 1O, ILIB, IL23R, SLC11A1, IL12B, CCR5, TNF, ILIO, CXCL12, BTNL2, ANKRD20A4, CD 14, P2X7, IL8, TLR2, and/or CD209.
    Type: Application
    Filed: May 16, 2013
    Publication date: May 21, 2015
    Inventors: Dave S.B. Hoon, Donald L. Morton, Connie G. Chiu, Kelly Chong
  • Publication number: 20150132364
    Abstract: The invention relates to an agent for the treatment or prevention of an allergic condition, such as asthma, in a mammal. The agent comprises fragments of a Mycobacterium tuberculosis-complex (MTB-C) strain. These particular fragments may be from a virulent MTB-C strain and/or in the form of a liposome composition. The agent may include further components, such as a liposome-forming agent and/or particular proteins from the MTB-C strain. A particular allergic response that may be treated by the agent of the invention is allergic asthma. A pharmaceutical composition comprising the agent is also provided. Administration of the agent described herein significantly attenuates airway hyperresponsiveness, eosinophilia and lymphocytosis in the airways of sensitized animals. The effectiveness of the agent exceeds on all the evaluated parameters the commercial vaccine BCG Danish 1331 Strain.
    Type: Application
    Filed: January 12, 2012
    Publication date: May 14, 2015
    Applicant: ARCHIVEL FARMA, S.L.
    Inventors: Pere Joan Cardona Iglesias, Isabel Amat Riera, Blanca Reyes Moreno, Maria Mercè Amat Fabregat
  • Patent number: 9017696
    Abstract: An adenoviral vector comprising a promoter further comprising a fragment of the 5? untranslated region of the CMV IE1 gene including intron A and a nucleic acid sequence encoding a pathogen or tumor antigen for use as a medicament.
    Type: Grant
    Filed: April 10, 2008
    Date of Patent: April 28, 2015
    Assignee: Isis Innovation Limited
    Inventors: Simon Draper, Arturo Reyes, Saranya Sridhar, Adrian Hill, Sarah Gilbert, Anna Goodman
  • Patent number: 9005579
    Abstract: The present invention relates to methods and compositions for use in modulating, including inhibiting the growth and/or reducing the virulence of gram-positive bacteria. The present invention provides methods and compositions for disrupting the cell wall and/or cell membrane in gram-positive bacteria such that cell wall or cell membrane target(s) are rendered exposed or accessible and sensitive to a modulation thereof. Methods for modulation of one or more gram-positive bacterial cell wall or cell membrane targets in a gram-positive bacteria are provided comprising disrupting the cell wall such that the cell wall or cell membrane target, which is particularly a sortase, is rendered exposed or accessible and sensitive to a modifying, modulating or binding agent, which is particularly an antibody or fragment thereof, wherein the cell wall or cell membrane target is inaccessible or relatively insensitive to the modifying, modulating or binding agent in the absence of cell wall disruption.
    Type: Grant
    Filed: January 5, 2011
    Date of Patent: April 14, 2015
    Assignees: Contrafect Corporation, The Rockfeller University
    Inventors: Robert C. Nowinski, Vincent A. Fischetti, Assaf Raz
  • Patent number: 9005908
    Abstract: The present invention relates to Mycobacterial infections and provides a method of diagnosing infections of Mycobacterium avium subsp. paratuberculosis (Map), the causative agent of Johne's disease. In addition, the invention also provides as kits for use in the diagnosis of Map infections and vaccines/immunogenic compositions.
    Type: Grant
    Filed: May 29, 2009
    Date of Patent: April 14, 2015
    Assignee: Moredun Research Institute
    Inventors: Karen Stevenson, Valerie Margaret Hughes
  • Patent number: 9005665
    Abstract: Disclosed herein are methods and compositions for treating or preventing Porcine reproductive and respiratory syndrome (PRRS) infection in a subject.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: April 14, 2015
    Assignee: Ohio State Innovation Foundation
    Inventors: Renukaradhya Gourapura, Varun Dwivedi, Basavaraj Binjawadagi, Jordi Torrelles
  • Publication number: 20150093414
    Abstract: Modified Rv3616c proteins and their use as medicaments, particularly for the prevention of reactivation of tuberculosis.
    Type: Application
    Filed: December 2, 2014
    Publication date: April 2, 2015
    Inventors: Normand BLAIS, Anne-Marie GELINAS, James BROWN, Dennis MURPHY, Pascal METTENS
  • Patent number: 8992942
    Abstract: The present invention is directed to reagents useful for generating immune responses to Mycobacterium tuberculosis and for diagnosing infection and disease in a subject that has been exposed to M. tuberculosis.
    Type: Grant
    Filed: August 4, 2011
    Date of Patent: March 31, 2015
    Assignee: Rutgers, The State University of New Jersey
    Inventor: Maria Laura Gennaro
  • Publication number: 20150071873
    Abstract: A first and a second identical or different mycobacterial immunogenic compositions, each comprising at least a Mycobacterium bovis bacillus Calmette-Guerin (BCG), an antigenically related non-pathogenic mycobacteria, or one or more immunogenic component(s) thereof, as therapeutic active ingredient(s) for use in the treatment of cancer by parenteral or oral administration of the first composition to a cancer patient before local administration of the second composition at tumor site. A method in vitro for monitoring cancer treatment by immunotherapy with BCG, antigenically related non-pathogenic mycobacteria, or immunogenic component(s) thereof, comprising assaying BCG-specific immune response in a patient.
    Type: Application
    Filed: January 24, 2013
    Publication date: March 12, 2015
    Inventors: Claire Biot, Matthew Albert, Cyrill Rentsch, Joel Gsponer
  • Patent number: 8974800
    Abstract: The present invention is directed to reagents useful for generating immune responses to Mycobacterium tuberculosis and for diagnosing infection and disease in a subject that has been exposed to M. tuberculosis.
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: March 10, 2015
    Assignee: Rutgers, The State University of New Jersey
    Inventor: Maria Laura Gennaro
  • Publication number: 20150064198
    Abstract: The invention is directed to compositions and methods for generating or enhancing the immune system of a patient against infection by a pathogen, and in particular MTB. Compositions of the invention contain one or more non-naturally occurring antigens that generate an effective cellular or humoral immune response to MTB and/or antibodies that are specifically reactive to mycolic acid or to the surface of MTB. The greater activity of the immune system generated by a vaccine of the invention involve an conjugation of peptides to increase in the generation of memory T cells that provide for a greater and/or longer lived or extended response to an MTB infection. Preferably a response involves an increased generation of antibodies that enhance immunity against MTB infection and promote an enhanced phagocytic response.
    Type: Application
    Filed: August 29, 2014
    Publication date: March 5, 2015
    Inventors: Gerald W. Fischer, Luke T. Daum, Clara Jebet Sei
  • Publication number: 20150050327
    Abstract: The invention provides liposome formulations comprising fragments from a Mycobacterium tuberculosis-complex strain, it also provides a Mycobacterium tuberculosis-complex strain, fragments of which may be incorporated into selected embodiments of the liposome formulation. The invention further provides suspensions and pharmaceutical compositions comprising the liposome formulations. Furthermore, it discloses the use of the liposome formulations for use in a method of treatment of the human or animal body by therapy, in particular for use in a method of treating or preventing tuberculosis, such as in preventing latent tuberculosis or in tuberculosis prophylaxis, optionally in combination therapy. The formulation of this invention contains sucrose and/or has a lower average particle size than conventional liposome-based agents of tuberculosis therapy, resulting in higher bioavailability and efficiency.
    Type: Application
    Filed: January 4, 2012
    Publication date: February 19, 2015
    Applicant: ARCHIVEL FARMA, S.L.
    Inventors: Pere J. Cardona Iglesias, Isabel Amat Riera, Blanca Reyes, Ariadna Selga, Mercè Amat
  • Patent number: 8932846
    Abstract: Recombinant immunogenic compositions, and methods for the manufacture and use, are provided for the prevention and treatment of intracellular pathogen diseases in humans and animals. The recombinant immunogenic compositions express high levels of recombinant proteins in vectors that do not harbor an antibiotic resistance marker (“unmarked”).
    Type: Grant
    Filed: June 12, 2008
    Date of Patent: January 13, 2015
    Assignee: The Regents of the University of California
    Inventors: Marcus A. Horwitz, Michael V. Tullius
  • Patent number: 8932608
    Abstract: Provided is a pharmaceutical composition that includes one or more inactivated Mycobacterium spp., which are preferably inactivated using gamma irradiation, and which is than formulated for mucosal or pulmonary delivery to a subject. The pharmaceutical compositions are useful for preventing or treating mycobacterium-associated infections in a subject, including a human subject.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: January 13, 2015
    Assignee: Mico Bio, Inc.
    Inventors: Jason Fisher, Jennifer Lighter
  • Patent number: 8932603
    Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.
    Type: Grant
    Filed: February 25, 2004
    Date of Patent: January 13, 2015
    Assignee: Vaccibody AS
    Inventors: Bjarne Bogen, Agnete Fredriksen Brunsvik, Inger Sandlie
  • Publication number: 20140377307
    Abstract: The present invention provides improved treatment methods by the administration of both an inhibitor of indoleamine-2,3-dioxygenase in addition to the administration of an additional therapeutic agent.
    Type: Application
    Filed: October 8, 2013
    Publication date: December 25, 2014
    Applicant: GEORGIA REGENTS RESEARCH INSTITUTE, INC.
    Inventors: DAVID MUNN, ANDREW MELLOR
  • Patent number: 8906389
    Abstract: The invention relates to methods and reagents for determining efficacy of vaccine, particularly of a tuberculosis vaccine.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: December 9, 2014
    Assignees: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V., Vakzine Projekt Management GmbH
    Inventors: Christiane Desel, Stefan H. E. Kaufmann, Silke Bandermann, Leander Grode
  • Patent number: 8906388
    Abstract: Method for detecting M. tuberculosis antigens, comprising: a) contacting a sample of a biological fluid with a solid support; b) adding an amount of a first antibody against at least one M. tuberculosis protein; c) screening for the presence of M. tuberculosis proteins in the biological fluid by adding an amount of a second antibody which binds to the first antibody, in a Miniblotter device.
    Type: Grant
    Filed: May 1, 2012
    Date of Patent: December 9, 2014
    Assignee: Instituto Nacional de Tecnologia Agropecuaria (INTA)
    Inventors: Alicia Elsa Alito, Elisa Bernardina Spolsky, Monica Virginia Pontino
  • Publication number: 20140356397
    Abstract: The present invention provides an immunomodulator for use in the treatment and/or control of a neoplastic disease in a patient intended to undergo immunogenic cell death therapy simultaneously, separately or sequentially with administration of the immunomodulator. The therapy can be selected from microwave irradiation, targeted radiotherapy, embolization, cryotherapy, ultrasound, high intensity focused ultrasound, cyberknife, hyperthermia, radiofrequency ablation, cryoablation, electrotome heating, hot water injection, alcohol injection, embolization, radiation exposure, photodynamic therapy, laser beam irradiation, and combinations thereof.
    Type: Application
    Filed: December 3, 2012
    Publication date: December 4, 2014
    Applicant: Immodulon Therapeutics Limited
    Inventors: Charles Akle, Satvinder Mudan, John Grange
  • Publication number: 20140356395
    Abstract: This document relates to methods and materials for producing immune responses against polypeptides involved in antibiotic resistance. For example, vaccines against polypeptides involved in antibiotic resistance as well as methods for vaccinating mammals against polypeptides involved in antibiotic resistance are provided.
    Type: Application
    Filed: August 18, 2014
    Publication date: December 4, 2014
    Inventor: Michael A. Barry
  • Patent number: 8883173
    Abstract: The current invention relates to the diagnosis and treatment of diseases resulting from infections by Mycobacterium avium subsp. paratuberculosis. In particular the invention relates to the use of an antigen selected among (a) a synthetic peptide 5P having the following formula: DPhe-NMeVal-Ile-Phe-Ala-OMe (SEQ ID NO: 1); (b) a lipopeptide L5P consisting of the synthetic peptide a) wherein the N-terminal phenylalanine residue is N-acylated with an eicosanoic acid acyl chain; (c) a variant of peptide a) or lipopeptide b) able to react with anti-Mycobacterium paratuberculosis antibodies; for in vitro detection or quantification of specific anti-Mycobacterium paratuberculosis antibodies in a biological sample.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: November 11, 2014
    Assignees: Institut National de la Sante et de la Recherche Medicale (Inserm), Institut National de la Recherche Agronomique, Institut Pasteur
    Inventors: Sylvie Bay, Franck Biet
  • Patent number: 8883431
    Abstract: Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen M. tuberculosis and their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter.
    Type: Grant
    Filed: November 19, 2012
    Date of Patent: November 11, 2014
    Assignee: Immport Therapeutics, Inc.
    Inventors: Philip Felgner, Xiaowu Liang, Maria Laura Gennaro
  • Patent number: 8877212
    Abstract: The present invention describes compositions for both diagnostic and therapeutic applications. In one embodiment, the present invention contemplates a method of identifying an active M. tuberculosis infection. In another embodiment, the present invention contemplates a method of monitoring a M. tuberculosis infection. In yet another embodiment, the present invention contemplates a method of monitoring a patient's response to treatment for an active M. tuberculosis infection. In a further embodiment, the present invention contemplates a method of monitoring a patient's response to treatment for an active M. tuberculosis infection.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: November 4, 2014
    Assignee: Trudeau Institute
    Inventors: Richard T. Robinson, Andrea M. Cooper
  • Publication number: 20140322268
    Abstract: Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: or a pharmaceutically acceptable salt thereof, wherein L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, Y1, Y2, Y3, Y4, R1, R2, R3, R4, R5, R6, are as defined herein. Pharmaceutical compositions, vaccine compositions, and related methods for inducing or enhancing immune responses, are also provided.
    Type: Application
    Filed: March 21, 2014
    Publication date: October 30, 2014
    Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTE
    Inventors: Steven G. REED, Darrick CARTER
  • Publication number: 20140314809
    Abstract: The invention provides a method of identifying an antigen from a pathogen or a disease antigen comprising the use of an adenoviral vector array comprising two or more different adenoviral vectors, wherein each adenoviral vector comprises a nucleic acid sequence encoding a different antigen of a pathogen. The adenoviral vectors are administered to antigen presenting cells (APCs) in vitro or to an animal in vivo. The immunogenicity of the antigen is measured by screening for an immune response from effector T lymphocytes in vitro and by screening for the absence of pathogen-induced disease onset in vivo.
    Type: Application
    Filed: April 19, 2013
    Publication date: October 23, 2014
    Inventors: Joseph T. Bruder, Imre Kovesdi, Duncan L. McVey, Douglas E. Brough, C. Richter King, Denise Louise Doolan, Joao Carlos Aguair, Daniel John Carucci, Martha Sedegah, Walter R. Weiss, Keith Limbach
  • Publication number: 20140302095
    Abstract: Provided herein are isolated polypeptides comprising the amino-terminal domain of Mycobacterium tuberculosis porin A (MtpA), wherein the polypeptide is a porin monomer. Also provided are isolated polypeptides comprising the carboxy-terminal domain of Mycobacterium tuberculosis porin A, wherein the polypeptide is a toxin. Also provided are methods of treating or preventing a Mycobacterium tuberculosis (Mtb) infection in a subject with or at risk of developing a Mtb infection. Further provided are chimeric porin polypeptides comprising a first polypeptide comprising an amino-terminal domain of Mycobacterium tuberculosis porin and a second polypeptide comprising an antigen and the use the chimeric porin polypeptides in methods of eliciting an immune response in a subject.
    Type: Application
    Filed: August 30, 2012
    Publication date: October 9, 2014
    Applicant: THE UAB RESEARCH FOUNDATION
    Inventors: Michael Niederweis, Olga Danilchanka